Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 30% of the global population but is often underdiagnosed. To fill this diagnostic gap, we developed a digital score reflecting presence and severity of MASLD. We fitted a machine learning model to electronic health records from 37,212 UK Biobank participants with proton density fat fraction measurements and/or a MASLD diagnosis to generate a “MASLD score”. In holdout testing, our model achieved areas under the receiver-operating curve of 0.83-0.84 for MASLD diagnosis and 0.90-0.91 for identifying MASLD-associated advanced fibrosis. MASLD score was significantly associated with MASLD risk factors, progression to cirrhosis, and mortality. External testing in 252,725 diverse American participants demonstrated consistent results, and hepatologist chart review showed MASLD score identified probable MASLD underdiagnosis. The MASLD score could improve early diagnosis and intervention of chronic liver disease by providing a non-invasive, low-cost method for population-wide screening of MASLD.
Competing Interest Statement
Dr. Do reported receiving grants from AstraZeneca, grants and nonfinancial support from Goldfinch Bio, being a scientific co-founder, consultant and equity holder for Pensieve Health (pending), and being a consultant for Variant Bio, all not related to this work. Dr. Bansal receives grant support from Pfizer and Histoindex and serves as a consultant for Madrigal, Intercept, Fibronostics, NOVONordisk, GSK, and The Kinetix Group. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Funding Statement
RC is supported by the National Institute of General Medical Sciences of the NIH (T32-GM007280). RD is supported by the National Institute of General Medical Sciences of the NIH (R35-GM124836).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Icahn School of Medicine at Mount Sinai gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Further information about the MSDW and BioMe datasets is available at https://labs.icahn.mssm.edu/msdw/ and https://icahn.mssm.edu/research/ipm/programs/biome-biobank/, respectively. The UK Biobank dataset can be accessed by applying through the Access Management System at https://bbams.ndph.ox.ac.uk/ams/. The All of Us dataset can be accessed by applying through the All of Us Research Hub at https://www.researchallofus.org/. Code used for the analyses have been deposited at https://doi.org/10.17632/78gc6dpwvm.1.
